MannKind Stock Price, News & Analysis (NASDAQ:MNKD)

$3.17 0.08 (2.59 %)
(As of 12/11/2017 02:42 AM ET)
Previous Close$3.09
Today's Range$3.05 - $3.22
52-Week Range$0.67 - $6.96
Volume2.10 million shs
Average Volume4.02 million shs
Market Capitalization$364.15 million
P/E RatioN/A
Dividend YieldN/A
Beta3.07

About MannKind (NASDAQ:MNKD)

MannKind logoMannKind Corporation is a biopharmaceutical company. The Company is focused on the discovery and development of therapeutic products for diseases, such as diabetes. Its product candidate is AFREZZA, which is an inhaled insulin used to control high blood sugar in adults with type I and type II diabetes and helps in glycemic control. AFREZZA consists of a dry formulation of human insulin delivered from a portable inhaler. AFREZZA utilizes its Technosphere formulation technology. Technosphere is a drug delivery platform that may allow the oral inhalation of a range of therapeutics. Technosphere powders are based on the Company's fumaryl diketopiperazine (FDKP), which is a potential of Hydrogen (pH)-sensitive organic molecule that self-assembles into small particles under acidic conditions. The Company has also created a range of breath-powered, dry powder inhalers. Its inhalers can be produced in both a reusable (chronic treatment) and a single-use (acute treatment) format.

Receive MNKD News and Ratings via Email

Sign-up to receive the latest news and ratings for MNKD and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryBiotechnology
SectorHealthcare
SymbolNASDAQ:MNKD
CUSIP56400P20
Phone+1-818-6615000

Debt

Debt-to-Equity Ratio-0.43%
Current Ratio0.31%
Quick Ratio0.28%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$174.76 million
Price / Sales2.16
Cash Flow$0.60 per share
Price / Cash5.25
Book Value($1.92) per share
Price / Book-1.65

Profitability

Trailing EPS($0.27)
Net Income$125.66 million
Net Margins-155.83%
Return on Equity-24.93%
Return on Assets-130.34%

Miscellaneous

Employees153
Outstanding Shares118,870,000

MannKind (NASDAQ:MNKD) Frequently Asked Questions

What is MannKind's stock symbol?

MannKind trades on the NASDAQ under the ticker symbol "MNKD."

How were MannKind's earnings last quarter?

MannKind Co. (NASDAQ:MNKD) issued its earnings results on Tuesday, November, 7th. The biopharmaceutical company reported ($0.31) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.20) by $0.11. The biopharmaceutical company earned $2.04 million during the quarter, compared to analysts' expectations of $2.56 million. MannKind had a negative net margin of 155.83% and a negative return on equity of 24.93%. The firm's quarterly revenue was down 98.7% compared to the same quarter last year. During the same quarter in the previous year, the company earned $1.30 earnings per share. View MannKind's Earnings History.

When will MannKind make its next earnings announcement?

MannKind is scheduled to release their next quarterly earnings announcement on Thursday, March, 15th 2018. View Earnings Estimates for MannKind.

Where is MannKind's stock going? Where will MannKind's stock price be in 2017?

4 brokers have issued 12-month target prices for MannKind's stock. Their forecasts range from $0.83 to $1.00. On average, they expect MannKind's stock price to reach $0.92 in the next year. View Analyst Ratings for MannKind.

What are Wall Street analysts saying about MannKind stock?

Here are some recent quotes from research analysts about MannKind stock:

  • 1. Maxim Group analysts commented, "MannKind raised (net $57.7M) in an equity offering recently. We had anticipated a larger offering that would provide a longer capital runway to get the Afrezza launch off the ground; one that would provide adequate support to launch a new product in a mature market." (11/1/2017)
  • 2. According to Zacks Investment Research, "Mannkind Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutic products for diseases such as diabetes, cancer, inflammatory and autoimmune diseases. The Company's lead product, the Technosphere Insulin System, consists of the Company's dry-powder Technosphere formulation of insulin and the Company's MedTone inhaler through which the powder is inhaled into the deep lung. " (10/11/2017)

Are investors shorting MannKind?

MannKind saw a increase in short interest during the month of November. As of November 15th, there was short interest totalling 30,952,103 shares, an increase of 1.9% from the October 31st total of 30,369,247 shares. Based on an average daily trading volume, of 4,401,961 shares, the short-interest ratio is presently 7.0 days. Approximately 32.3% of the shares of the stock are sold short.

Who are some of MannKind's key competitors?

Who are MannKind's key executives?

MannKind's management team includes the folowing people:

  • Kent Kresa, Chairman of the Board (Age 78)
  • Michael E. Castagna Pharm.D., Chief Executive Officer, Director (Age 40)
  • Rosabel R. Alinaya, Acting Chief Financial Officer, Senior Vice President, Chief Accounting Officer (Age 56)
  • Steven B Binder, Chief Financial Officer, Principal Accounting Officer (Age 54)
  • Linda Adreveno, Senior Vice President - Human Resources (Age 60)
  • Joseph Kocinsky, Chief Technology Officer, Corporate Vice President (Age 52)
  • David B. Thomson Ph.D., J.D., Corporate Vice President, General Counsel, Corporate Secretary (Age 49)
  • Patrick McCauley J.D., Chief Commercial Officer
  • Stuart A. Tross Ph.D., Chief People Officer (Age 49)
  • James Samuel Shannon M.D., Director (Age 60)

Who owns MannKind stock?

MannKind's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Dimensional Fund Advisors LP (0.11%), Bank of New York Mellon Corp (0.09%), Dupont Capital Management Corp (0.10%), Wells Fargo & Company MN (0.08%) and Macquarie Group Ltd. (0.06%). Company insiders that own MannKind stock include Kent Kresa, Matthew J Pfeffer, Michael Castagna, Raymond W Urbanski and Rosabel Realica Alinaya. View Institutional Ownership Trends for MannKind.

Who bought MannKind stock? Who is buying MannKind stock?

MannKind's stock was purchased by a variety of institutional investors in the last quarter, including Dimensional Fund Advisors LP, Dupont Capital Management Corp, Macquarie Group Ltd., Wells Fargo & Company MN and Bank of New York Mellon Corp. Company insiders that have bought MannKind stock in the last two years include Kent Kresa, Matthew J Pfeffer, Michael Castagna and Rosabel Realica Alinaya. View Insider Buying and Selling for MannKind.

How do I buy MannKind stock?

Shares of MannKind can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is MannKind's stock price today?

One share of MannKind stock can currently be purchased for approximately $3.17.

How big of a company is MannKind?

MannKind has a market capitalization of $364.15 million and generates $174.76 million in revenue each year. The biopharmaceutical company earns $125.66 million in net income (profit) each year or ($0.27) on an earnings per share basis. MannKind employs 153 workers across the globe.

How can I contact MannKind?

MannKind's mailing address is 30930 Russell Ranch Rd Ste 301, WESTLAKE VILLAGE, CA 91362-7378, United States. The biopharmaceutical company can be reached via phone at +1-818-6615000 or via email at [email protected]


MarketBeat Community Rating for MannKind (MNKD)

Community Ranking:  2.1 out of 5 (star star)
Outperform Votes:  237 (Vote Outperform)
Underperform Votes:  327 (Vote Underperform)
Total Votes:  564
MarketBeat's community ratings are surveys of what our community members think about MannKind and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

MannKind (NASDAQ:MNKD) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 1.751.601.501.50
Ratings Breakdown: 2 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
3 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
4 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
4 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $0.92$0.66$0.66$1.50
Price Target Upside: 71.85% downside79.69% downside64.71% downside32.30% upside

MannKind (NASDAQ:MNKD) Consensus Price Target History

Price Target History for MannKind (NASDAQ:MNKD)

MannKind (NASDAQ:MNKD) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/8/2017HC WainwrightReiterated RatingBuyN/AView Rating Details
11/1/2017Maxim GroupReiterated RatingBuy -> HoldN/AView Rating Details
5/22/2017J P Morgan Chase & CoReiterated RatingUnderweightHighView Rating Details
5/11/2017Piper Jaffray CompaniesSet Price TargetSell$1.00MediumView Rating Details
5/8/2017S&P Equity ResearchLower Price Target$1.04 -> $0.83HighView Rating Details
6/1/2016Royal Bank Of CanadaLower Price TargetUnderperform$1.00 -> $0.15N/AView Rating Details
4/28/2016JMP SecuritiesReiterated RatingHoldN/AView Rating Details
4/1/2016Goldman Sachs GroupReiterated RatingSellN/AView Rating Details
1/6/2016Griffin SecuritiesUpgradeNeutral -> Buy$4.00N/AView Rating Details
(Data available from 12/11/2015 forward)

Earnings

MannKind (NASDAQ:MNKD) Earnings History and Estimates Chart

Earnings by Quarter for MannKind (NASDAQ:MNKD)

MannKind (NASDAQ MNKD) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/15/2018        
11/7/2017Q3 2017($0.20)($0.31)$2.56 million$2.04 millionViewN/AView Earnings Details
8/7/2017Q2 2017($0.25)($0.35)$2.75 million$2.16 millionViewListenView Earnings Details
5/10/2017Q1 2017($0.09)($0.17)$3.50 million$3.00 millionViewN/AView Earnings Details
3/16/2017Q4 2016($0.20)($0.19)$6.00 million$12.40 millionViewN/AView Earnings Details
11/9/2016Q3 2016($0.06)$0.26$2.00 million$162.35 millionViewListenView Earnings Details
8/8/2016Q2($0.06)($0.07)$0.03 millionViewN/AView Earnings Details
5/9/2016Q116($0.04)($0.06)ViewN/AView Earnings Details
3/14/2016Q4($0.05)($0.66)$0.35 millionViewN/AView Earnings Details
11/9/2015Q315($0.07)($0.08)ViewN/AView Earnings Details
8/10/2015Q215($0.08)($0.07)$0.53 millionViewListenView Earnings Details
5/7/2015Q115($0.08)($0.08)$5.40 millionViewListenView Earnings Details
2/24/2015Q414($0.09)($0.09)$3.13 millionViewListenView Earnings Details
11/3/2014Q314$0.09($0.09)$66.60 millionViewListenView Earnings Details
8/11/2014Q214($0.11)($0.19)ViewListenView Earnings Details
5/12/2014Q114($0.13)($0.14)ViewListenView Earnings Details
2/18/2014Q4($0.14)($0.16)$0.43 millionViewListenView Earnings Details
11/4/2013Q313($0.14)($0.17)ViewListenView Earnings Details
8/9/2013Q2 2013($0.14)($0.16)ViewN/AView Earnings Details
5/9/2013Q1 2013($0.15)($0.15)ViewListenView Earnings Details
2/11/2013Q4 2012($0.19)($0.23)ViewListenView Earnings Details
11/1/2012Q312($0.24)($0.22)ViewN/AView Earnings Details
8/7/2012($0.24)($0.23)ViewN/AView Earnings Details
5/9/2012($0.23)($0.27)ViewN/AView Earnings Details
2/22/2012($0.32)($0.30)ViewN/AView Earnings Details
11/3/2011($0.32)($0.31)ViewN/AView Earnings Details
8/4/2011($0.30)($0.37)ViewN/AView Earnings Details
5/9/2011($0.29)($0.34)ViewN/AView Earnings Details
2/10/2011($0.40)($0.33)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

MannKind (NASDAQ:MNKD) Earnings Estimates

Current Year EPS Consensus Estimate: $-1.13 EPS
Next Year EPS Consensus Estimate: $-0.98 EPS

Dividends

Dividend History for MannKind (NASDAQ:MNKD)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

MannKind (NASDAQ MNKD) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 1.10%
Institutional Ownership Percentage: 12.18%
Insider Trades by Quarter for MannKind (NASDAQ:MNKD)
Institutional Ownership by Quarter for MannKind (NASDAQ:MNKD)

MannKind (NASDAQ MNKD) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/13/2017Kent KresaDirectorBuy166,600$6.00$999,600.00View SEC Filing  
8/10/2017Raymond W UrbanskiCMOSell296$1.15$340.40View SEC Filing  
6/30/2017Rosabel Realica AlinayaSVPBuy2,000$1.23$2,460.00View SEC Filing  
1/3/2017Matthew J PfefferCEOBuy4,540$0.54$2,451.60View SEC Filing  
1/3/2017Rosabel Realica AlinayaSVPBuy9,043$0.54$4,883.22View SEC Filing  
8/26/2016Michael CastagnaInsiderBuy17,500$0.78$13,650.00View SEC Filing  
8/24/2016Michael CastagnaInsiderBuy15,000$0.87$13,050.00View SEC Filing  
8/23/2016Michael CastagnaInsiderBuy25,000$0.94$23,500.00View SEC Filing  
8/15/2016Matthew J PfefferCEOBuy25,000$0.99$24,750.00View SEC Filing  
8/12/2016Michael CastagnaInsiderBuy25,000$1.00$25,000.00View SEC Filing  
5/17/2016Michael CastagnaInsiderBuy50,000$0.93$46,500.00View SEC Filing  
4/24/2015Hakan EdstromCEOSell73,460$4.83$354,811.80View SEC Filing  
3/27/2015Hakan EdstromCEOSell73,460$5.21$382,726.60View SEC Filing  
2/10/2015Hakan EdstromCEOSell73,460$7.75$569,315.00View SEC Filing  
2/5/2015David ThomsonVPSell80,000$7.00$560,000.00View SEC Filing  
1/5/2015Diane PalumboVPSell188,999$5.95$1,124,544.05View SEC Filing  
11/24/2014David ThomsonVPSell118,114$6.14$725,219.96View SEC Filing  
10/3/2014Juergen MartensVPSell63,800$5.48$349,624.00View SEC Filing  
8/27/2014Juergen MartensVPSell417$7.60$3,169.20View SEC Filing  
8/7/2014David ThomsonVPSell30,000$8.16$244,800.00View SEC Filing  
7/21/2014Juergen MartensVPSell26,458$9.65$255,319.70View SEC Filing  
7/15/2014Diane PalumboVPSell17,901$10.01$179,189.01View SEC Filing  
7/1/2014Matthew J PfefferCFOSell20,000$10.44$208,800.00View SEC Filing  
6/30/2014Hakan EdstromCOOBuy1,692$4.42$7,478.64View SEC Filing  
6/27/2014Juergen MartensVPSell25,417$10.53$267,641.01View SEC Filing  
6/26/2014David ThomsonVPSell30,000$10.51$315,300.00View SEC Filing  
6/20/2014Juergen MartensVPSell1,458$10.34$15,075.72View SEC Filing  
6/16/2014Diane PalumboVPSell17,902$10.59$189,582.18View SEC Filing  
6/5/2014Juergen MartensVPSell120,000$11.00$1,320,000.00View SEC Filing  
6/4/2014David ThomsonVPSell133,000$9.95$1,323,350.00View SEC Filing  
6/3/2014Diane PalumboVPSell52,957$9.50$503,091.50View SEC Filing  
5/23/2014Juergen MartensVPSell25,000$7.65$191,250.00View SEC Filing  
5/19/2014Juergen MartensVPSell76,899$7.50$576,742.50View SEC Filing  
5/15/2014Diane PalumboVPSell18,176$7.06$128,322.56View SEC Filing  
1/24/2014Juergen MartensVPSell50,000$5.56$278,000.00View SEC Filing  
12/31/2013Hakan EdstromCOOBuy1,589$4.53$7,198.17View SEC Filing  
12/20/2013Juergen MartensVPSell32,054$5.00$160,270.00View SEC Filing  
12/11/2013David ThomsonVPSell150,000$5.00$750,000.00View SEC Filing  
11/29/2013Juergen MartensVPSell48,057$5.01$240,765.57View SEC Filing  
11/15/2013Diane PalumboVPSell25,000$5.02$125,500.00View SEC Filing  
8/28/2013David ThomsonVPSell19,204$5.78$110,999.12View SEC Filing  
8/26/2013Juergen MartensVPSell20,000$5.52$110,400.00View SEC Filing  
8/1/2013Matthew J PfefferCFOSell10,000$8.00$80,000.00View SEC Filing  
7/2/2013Matthew J PfefferCFOSell10,000$7.00$70,000.00View SEC Filing  
6/30/2013Diane PalumboVPBuy1,610$1.96$3,155.60View SEC Filing  
6/30/2013Matthew J PfefferCFOBuy7,448$1.96$14,598.08View SEC Filing  
6/3/2013Diane PalumboVPSell66,849$7.50$501,367.50View SEC Filing  
5/16/2013Diane PalumboVPSell26,829$5.25$140,852.25View SEC Filing  
5/15/2013Matthew J PfefferCFOSell10,000$5.00$50,000.00View SEC Filing  
12/31/2012Matthew J PfefferCFOBuy1,056$1.95$2,059.20View SEC Filing  
12/21/2012Alfred E MannMajor ShareholderBuy40,000,000$2.59$103,600,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

MannKind (NASDAQ MNKD) News Headlines

Source:
DateHeadline
Why MannKind Corporation Dipped 4.8% in November - Motley FoolWhy MannKind Corporation Dipped 4.8% in November - Motley Fool
www.fool.com - December 7 at 5:30 PM
Why MannKind Corporation Dipped 4.8% in NovemberWhy MannKind Corporation Dipped 4.8% in November
finance.yahoo.com - December 5 at 5:02 PM
MannKind (MNKD) Rating Lowered to Hold at BidaskClubMannKind (MNKD) Rating Lowered to Hold at BidaskClub
www.americanbankingnews.com - December 2 at 12:40 PM
MannKind Corporation (MNKD) Given Average Rating of "Hold" by BrokeragesMannKind Corporation (MNKD) Given Average Rating of "Hold" by Brokerages
www.americanbankingnews.com - November 29 at 1:38 AM
Implied Volatility Surging for MannKind (MNKD) Stock OptionsImplied Volatility Surging for MannKind (MNKD) Stock Options
finance.yahoo.com - November 27 at 4:55 PM
ETFs with exposure to MannKind Corp. : November 27, 2017ETFs with exposure to MannKind Corp. : November 27, 2017
finance.yahoo.com - November 27 at 4:55 PM
MannKind Corporation (MNKD) Downgraded by ValuEngine to "Strong Sell"MannKind Corporation (MNKD) Downgraded by ValuEngine to "Strong Sell"
www.americanbankingnews.com - November 26 at 12:56 PM
MannKind: Afrezza Scripts And Revenue Rising - Is It Enough? - Seeking AlphaMannKind: Afrezza Scripts And Revenue Rising - Is It Enough? - Seeking Alpha
seekingalpha.com - November 25 at 9:33 AM
An Integrated BioSci Research On MannKind Corporation: How To Unlock Value? - Seeking AlphaAn Integrated BioSci Research On MannKind Corporation: How To Unlock Value? - Seeking Alpha
seekingalpha.com - November 23 at 6:32 AM
MannKind Corp. :MNKD-US: Earnings Analysis: Q3, 2017 By the Numbers : November 21, 2017MannKind Corp. :MNKD-US: Earnings Analysis: Q3, 2017 By the Numbers : November 21, 2017
finance.yahoo.com - November 22 at 5:24 AM
MannKind CEO Michael Castagna on Whats Ahead for the BiotechMannKind CEO Michael Castagna on What's Ahead for the Biotech
www.fool.com - November 21 at 7:06 AM
MannKind CEO Michael Castagna on What's Ahead for the BiotechMannKind CEO Michael Castagna on What's Ahead for the Biotech
finance.yahoo.com - November 21 at 7:06 AM
MannKind: Afrezza Scripts Remain Flat As Holiday Season Approaches - Seeking AlphaMannKind: Afrezza Scripts Remain Flat As Holiday Season Approaches - Seeking Alpha
seekingalpha.com - November 19 at 8:08 AM
MannKind: Insider Trading, Short Interest, And Catalysts, Oh My - Seeking AlphaMannKind: Insider Trading, Short Interest, And Catalysts, Oh My - Seeking Alpha
seekingalpha.com - November 17 at 5:29 PM
MannKind Corp. – Value Analysis (NASDAQ:MNKD) : November 15, 2017MannKind Corp. – Value Analysis (NASDAQ:MNKD) : November 15, 2017
finance.yahoo.com - November 17 at 5:29 PM
MannKind Corp. breached its 50 day moving average in a Bearish Manner : MNKD-US : November 14, 2017MannKind Corp. breached its 50 day moving average in a Bearish Manner : MNKD-US : November 14, 2017
finance.yahoo.com - November 15 at 6:26 AM
Analyzing MannKind Corporation (MNKD) and Its PeersAnalyzing MannKind Corporation (MNKD) and Its Peers
www.americanbankingnews.com - November 14 at 5:18 AM
Does MannKind Have Enough Funds to Support the Afrezza Launch? 3Q Earnings Disaster Leaves QuestionsDoes MannKind Have Enough Funds to Support the Afrezza Launch? 3Q Earnings Disaster Leaves Questions
finance.yahoo.com - November 12 at 7:44 AM
MannKind Has Much Room for Upside in Diabetes Market: Here’s WhyMannKind Has Much Room for Upside in Diabetes Market: Here’s Why
finance.yahoo.com - November 12 at 7:44 AM
MannKind Corporation (MNKD) Sees Large Increase in Short InterestMannKind Corporation (MNKD) Sees Large Increase in Short Interest
www.americanbankingnews.com - November 11 at 1:48 AM
EARNINGS SUMMARY: Details of MannKind Corp. Q3 Earnings ReportEARNINGS SUMMARY: Details of MannKind Corp. Q3 Earnings Report
www.rttnews.com - November 9 at 1:54 AM
Heres Why MannKind Corporation Is Sinking - Motley FoolHere's Why MannKind Corporation Is Sinking - Motley Fool
www.fool.com - November 8 at 8:53 PM
5 Things You Don't Want to Overlook in MannKind Corporation's Q3 Update5 Things You Don't Want to Overlook in MannKind Corporation's Q3 Update
finance.yahoo.com - November 8 at 8:53 PM
5 Things You Dont Want to Overlook in MannKind Corporations Q3 Update5 Things You Don't Want to Overlook in MannKind Corporation's Q3 Update
www.fool.com - November 8 at 8:49 PM
MannKinds (MNKD) CEO Michael Castagna on Q3 2017 Results - Earnings Call Transcript - Seeking AlphaMannKind's (MNKD) CEO Michael Castagna on Q3 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - November 8 at 3:48 PM
MannKind Corporation Reports 2017 Third Quarter Financial Results - GlobeNewswire (press release)MannKind Corporation Reports 2017 Third Quarter Financial Results - GlobeNewswire (press release)
globenewswire.com - November 8 at 3:48 PM
MannKind Corporation to Host Earnings CallMannKind Corporation to Host Earnings Call
finance.yahoo.com - November 8 at 3:48 PM
MannKind Corporation Reports 2017 Third Quarter Financial ResultsMannKind Corporation Reports 2017 Third Quarter Financial Results
finance.yahoo.com - November 8 at 3:48 PM
MannKind reports 3Q lossMannKind reports 3Q loss
finance.yahoo.com - November 8 at 3:48 PM
Edited Transcript of MNKD earnings conference call or presentation 7-Nov-17 10:00pm GMTEdited Transcript of MNKD earnings conference call or presentation 7-Nov-17 10:00pm GMT
finance.yahoo.com - November 8 at 3:48 PM
Here's Why MannKind Corporation Is SinkingHere's Why MannKind Corporation Is Sinking
finance.yahoo.com - November 8 at 3:48 PM
Heres Why MannKind Corporation Is SinkingHere's Why MannKind Corporation Is Sinking
www.fool.com - November 8 at 1:52 PM
MannKind Corporation (MNKD) Receives "Buy" Rating from HC WainwrightMannKind Corporation (MNKD) Receives "Buy" Rating from HC Wainwright
www.americanbankingnews.com - November 8 at 9:50 AM
MannKind Corporation (MNKD) Issues Quarterly  Earnings ResultsMannKind Corporation (MNKD) Issues Quarterly Earnings Results
www.americanbankingnews.com - November 7 at 7:26 PM
MannKind Scripts Rebound - Why The Equity Is Volatile - Seeking AlphaMannKind Scripts Rebound - Why The Equity Is Volatile - Seeking Alpha
seekingalpha.com - November 7 at 6:57 AM
Why MannKind Corporation Stock Vaulted Higher in October - Motley FoolWhy MannKind Corporation Stock Vaulted Higher in October - Motley Fool
www.fool.com - November 7 at 6:57 AM
Critical Analysis: MannKind (MNKD) vs. Its PeersCritical Analysis: MannKind (MNKD) vs. Its Peers
www.americanbankingnews.com - November 7 at 1:28 AM
Why MannKind Corporation Stock Vaulted Higher in OctoberWhy MannKind Corporation Stock Vaulted Higher in October
www.fool.com - November 6 at 2:19 PM
[$$] MannKinds Cash Runway Looks Too Short[$$] MannKind's Cash Runway Looks Too Short
finance.yahoo.com - November 4 at 5:26 AM
MannKind Corp. breached its 50 day moving average in a Bullish Manner : MNKD-US : November 3, 2017MannKind Corp. breached its 50 day moving average in a Bullish Manner : MNKD-US : November 3, 2017
finance.yahoo.com - November 4 at 5:25 AM
MannKind Corporation (MNKD) Given Consensus Recommendation of "Hold" by BrokeragesMannKind Corporation (MNKD) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - November 4 at 1:40 AM
MannKind Corporation (MNKD) Set to Announce Quarterly Earnings on TuesdayMannKind Corporation (MNKD) Set to Announce Quarterly Earnings on Tuesday
www.americanbankingnews.com - October 31 at 2:48 PM
MannKind Corporation to Hold 2017 Third Quarter Financial Results Conference Call on November 7, 2017 - GlobeNewswire (press release)MannKind Corporation to Hold 2017 Third Quarter Financial Results Conference Call on November 7, 2017 - GlobeNewswire (press release)
globenewswire.com - October 29 at 6:56 AM
MannKind Corporation to Hold 2017 Third Quarter Financial Results Conference Call on November 7, 2017MannKind Corporation to Hold 2017 Third Quarter Financial Results Conference Call on November 7, 2017
finance.yahoo.com - October 28 at 8:14 AM
Short Interest in MannKind Corporation (MNKD) Rises By 11.3%Short Interest in MannKind Corporation (MNKD) Rises By 11.3%
www.americanbankingnews.com - October 26 at 1:40 AM
MannKind (MNKD), BIOMM Submit Registration Dossier in BrazilMannKind (MNKD), BIOMM Submit Registration Dossier in Brazil
www.streetinsider.com - October 25 at 7:32 AM
MannKind: Bankruptcy Fears Fade AwayMannKind: Bankruptcy Fears Fade Away
seekingalpha.com - October 25 at 7:32 AM
MannKind And Biomm SA Announce The Filing Of Afrezza In Brazil - While Debt Renegotiation Happens - Seeking AlphaMannKind And Biomm SA Announce The Filing Of Afrezza In Brazil - While Debt Renegotiation Happens - Seeking Alpha
seekingalpha.com - October 24 at 6:20 AM
MannKind: The Proof Is In The Pie - MannKind Corporation ... - Seeking AlphaMannKind: The Proof Is In The Pie - MannKind Corporation ... - Seeking Alpha
seekingalpha.com - October 24 at 6:20 AM
MannKind and BIOMM Submit Registration Dossier to Brazilian Health Regulatory Agency (ANVISA)MannKind and BIOMM Submit Registration Dossier to Brazilian Health Regulatory Agency (ANVISA)
finance.yahoo.com - October 24 at 6:20 AM

SEC Filings

MannKind (NASDAQ:MNKD) SEC Filings

DateFilerForm TypeView
12/06/2017
3:09 PM
MannKind (Filer)
Form CT ORDER
View Filing

Social Media

Financials

MannKind (NASDAQ:MNKD) Income Statement, Balance Sheet and Cash Flow Statement

Chart

MannKind (NASDAQ MNKD) Stock Chart for Monday, December, 11, 2017

Loading chart…

This page was last updated on 12/11/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.